Mindfulness-based cognitive therapy reduces parenting anxiety and enhances quality of life in patients with breast cancer

Table 2 Clinical characteristics of participants, n (%)

Indicator	Conventional treatment group (n = 123)	MBCT group (n = 126)	t/χ2	P value
Breast cancer stage			0.069	0.793
I	19 (15.45)	21 (16.67)
II	104 (84.55)	105 (83.33)
Disease duration (year)			0.406	0.816
1-5	35 (28.46)	40 (31.75)
5-10	40 (32.52)	41 (32.54)
10-15	48 (39.02)	45 (35.71)
BMI, mean ± SD	22.90 ± 3.60	22.30 ± 3.30	1.369	0.172
Relapse			0.000	1.000
Yes	2 (1.63)	3 (2.38)
No	121 (98.37)	123 (97.62)
Tumor size (mm)			5.319	0.07
≤ 20	51 (41.46)	59 (46.83)
20-50	57 (46.34)	42 (33.33)
> 50	15 (12.20)	25 (19.84)
TNM			0.549	0.76
T1N1M0	13 (10.57)	17 (13.49)
T2N1M0	64 (52.03)	65 (51.59)
T2N0M0	46 (37.46)	44 (34.92)
Type of surgery			4.355	0.037
Mastectomy	68 (55.28)	53 (42.06)
Lumpectomy	65 (52.72)	73 (57.94)
Chemotherapy scheme			2.553	0.279
AC-T	86 (69.92)	83 (65.87)
TAC	9 (7.32)	17 (13.49)
TC	28 (22.76)	26 (20.63)
Breast reconstruction			3.089	0.079
Yes	16 (13.01)	27 (21.43)
No	107 (86.99)	99 (78.57)
ALND			0.096	0.953
Yes	58 (47.15)	57 (45.24)
No	63 (51.22)	67 (53.17)
Not reported	2 (1.63)	2 (1.59)

MBCT: Mindfulness-based cognitive therapy; BMI: Body mass index; ALND: Axillary lymph node dissection; AC-T: Use doxorubicin and cyclophosphamide, followed by paclitaxel or sometimes docetaxel after completing the AC phase; TAC: Simultaneously using Adriamycin, Cytoxan, and Docetaxel; TC: Simultaneously using Taxotere and Carboplatin.